Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correction: Higher HbA1c Measurement Quality Standards are Needed for Follow-Up and Diagnosis: Experience and Analyses from Germany.
Heinemann L, Kaiser P, Freckmann G, Grote-Koska D, Kerner W, Landgraf R, Merker L, Müller UA, Müller-Wieland D, Roth J, Spannagl M, Wallaschofski H, Nauck M. Heinemann L, et al. Among authors: merker l. Horm Metab Res. 2018 Oct;50(10):e5. doi: 10.1055/a-0746-4288. Epub 2018 Sep 21. Horm Metab Res. 2018. PMID: 30241106 No abstract available.
Validation of a risk prediction model for early chronic kidney disease in patients with type 2 diabetes: Data from the German/Austrian Diabetes Prospective Follow-up registry.
Kress S, Bramlage P, Holl RW, Möller CD, Mühldorfer S, Reindel J, Seufert J, Landgraf R, Merker L, Meyhöfer SM, Danne T, Fasching P, Mertens PR, Wanner C, Lanzinger S. Kress S, et al. Among authors: merker l. Diabetes Obes Metab. 2023 Mar;25(3):776-784. doi: 10.1111/dom.14925. Epub 2022 Dec 20. Diabetes Obes Metab. 2023. PMID: 36444743
Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial.
Roden M, Merker L, Christiansen AV, Roux F, Salsali A, Kim G, Stella P, Woerle HJ, Broedl UC; EMPA-REG EXTEND™ MONO investigators. Roden M, et al. Among authors: merker l. Cardiovasc Diabetol. 2015 Dec 23;14:154. doi: 10.1186/s12933-015-0314-0. Cardiovasc Diabetol. 2015. PMID: 26701110 Free PMC article. Clinical Trial.
Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes.
Haering HU, Merker L, Christiansen AV, Roux F, Salsali A, Kim G, Meinicke T, Woerle HJ, Broedl UC; EMPA-REG EXTEND™ METSU investigators. Haering HU, et al. Among authors: merker l. Diabetes Res Clin Pract. 2015 Oct;110(1):82-90. doi: 10.1016/j.diabres.2015.05.044. Epub 2015 May 29. Diabetes Res Clin Pract. 2015. PMID: 26324220 Clinical Trial.
[Nephropathy in diabetes].
Merker L. Merker L. MMW Fortschr Med. 2021 Apr;163(8):48-51. doi: 10.1007/s15006-021-9782-1. MMW Fortschr Med. 2021. PMID: 33904093 Review. German. No abstract available.
Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.
Häring HU, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Woerle HJ, Broedl UC; EMPA-REG METSU Trial Investigators. Häring HU, et al. Among authors: merker l. Diabetes Care. 2013 Nov;36(11):3396-404. doi: 10.2337/dc12-2673. Epub 2013 Aug 20. Diabetes Care. 2013. PMID: 23963895 Free PMC article. Clinical Trial.
65 results